Lupin Limited — Board Meeting, 05-08-2025: Outcome of Board Meeting

Lupin has announced a board meeting where it approved the financial results for the quarter ended June 30, 2025. The company delivered strong performance, with Consolidated Revenue from Operations rising to ₹ 6,268.34 Cr. Net Profit for the quarter jumped significantly to ₹ 1,221.46 Cr, showing solid growth both quarter-on-quarter and year-on-year. A key strategic update during the period was the acquisition of Renascience Pharma Limited, UK, for ₹ 136.16 Cr, bolstering Lupin's international presence.